A PhaseII Study of Bevacizumab in Combination with S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer reviously treated with platinum based chemotherapy
- Conditions
- on-Squamous Non-Small-Cell Lung Cancer
- Registration Number
- JPRN-UMIN000005486
- Lead Sponsor
- Hiroshima citizens hospital Department of Medical Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 34
Not provided
(1) Previously untreated with platinum doublet (2) transfusion or G-CSF within 2weeks prior to enrollment (3) Severe renal function disorder, 2+ or higher proteinuria within 2 weeks prior to enrollment (4) History of severe drug allergy (5) History of active double cancer within 5 years (6) History of active severe infections (7) Patients who have fever of over 38 degrees (8) Continuous administration of steroid drug (9) Severe cardiac disease (10) History of thromboembolism or severe pulmonary disease (11) History of GI bleeding,ileus,GI ulceration (12) massive pleural or pericardial effusion,ascites (13) Symptomatic brain metastases (14) Uncontrollable hypertension or diabetes mellitus (15) Uncontrollable diarrhea (16) Wound of unrecovery (17) Traumatic fracture of unrecovery (18) bleeding diathesis or receiving anticoagulant drug(except Aspirin under 324mg/day) (19) History of pregnancy or lactation (20) Evaluated to be ineligible by a physician for other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method progression free survival,time to treatment failur,overall survival,and safety